GMED logo

GLOBUS MEDICAL INC - A

GMEDNYSE
πŸ† #883 by market capEarnings Nov 4US Equity
$75.76β–² $0.99 (+1.31%)
After hours Β· at close
πŸ””
Track GMED
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.3%
7dβ–² 0.7%
14dβ–² 1.5%
30dβ–Ό 8.8%
ytdβ–Ό 13.3%
1yβ–² 34.2%
🏦Market Cap
$10.28B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+19.7%
Healthy
πŸ“ŠGross Margin
68.5%
High
πŸ’΅FCF Margin
23.9%
Strong
βš–οΈP/S Ratio
3.2x
Fair
Otter Score
76
Good

Trading Snapshot

Day Range
$74.56 – $77.18
52-Week Range
$54.15 – $101.40
Volume
$2.78B
Avg Volume
$3.69B
Shares Outstanding
135.7M
Next Earnings
Nov 30, 2026

Fundamentals Snapshot

Annual Revenue
$2.94B
Last Q Revenue
$790M
P/E Ratio
18.7
P/S Ratio
3.2x
EPS (TTM)
$3.91
Dividend Yield
β€”
Dilution (1yr)
βˆ’1.8%

Why Investors Own GMED

  • βœ“High-growth profile β€” revenue up +59.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 61% gross margin and 28% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GMED logo

GLOBUS MEDICAL INC - A

GMED
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.9Bβ–² +16.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.4%β–² +14.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$480Mβ–² +189.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$589Mβ–² +45.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
137.2Mβ–Ό βˆ’1.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$408Mβ–² +$160M YoY
StockOtter Β· stockotter.space

About GLOBUS MEDICAL INC - A

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Ratings

β“˜
Consensus
Buy
23 analysts
Strong Buy4
Buy12
Hold7
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates